The $1.1bn acquisition of drug-eluting balloon developer MedAlliance will help Cordis return to its roots as an innovative leader in interventional cardiology.

The company has developed a method to convert DICOM images into 3D holograms that can be projected onto VR headsets. Medtech Insight caught up with CEO Alison Sundset to find out how Holocare is paving the way for a more integrated, collaborative form of pre-surgical planning.

The diagnostic company has secured more government funding for DeepView, a product it has developed to assess the healing of certain types of wound. In total, BARDA has supported SpectralMD with almost a quarter of a billion dollars.

The surgical robotics start-up may be de-listed from the New York Stock Exchange (NYSE) due to its low current share price. Some analysts believe the company can survive long enough to earn FDA de novo clearance for its robotic surgical system.

The UK-based company is hoping to quickly take market share with its blood-based diagnostic that uses epigenetic data to assist cancer diagnosis.

The cash will be used to extend the company’s development runway “well into 2025.”